




Instance: composition-en-8fdef97116c9e46e3458e3dc3216f0d9
InstanceOf: CompositionUvEpi
Title: "Composition for orserdu Package Leaflet"
Description:  "Composition for orserdu Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp8fdef97116c9e46e3458e3dc3216f0d9)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - orserdu"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What ORSERDU is and what it is used for </li>
<li>What you need to know before you take ORSERDU </li>
<li>How to take ORSERDU </li>
<li>Possible side effects </li>
<li>How to store ORSERDU </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What orserdu is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What orserdu is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What ORSERDU is </p>
<p>ORSERDU contains the active substance elacestrant which belongs to a group of medicines called 
selective estrogen receptor degraders. </p>
<p>What ORSERDU is used for </p>
<p>This medicine is used to treat postmenopausal women and adult men who have a specific type of 
breast cancer that is advanced or has spread to other parts of the body (metastatic). It can be used to 
treat breast cancer that is estrogen receptor (ER)-positive, meaning that the cancer cells have receptors 
for the hormone oestrogen on their surface, and that is human epidermal growth factor receptor 2 
(HER2)-negative, meaning that cancer cells have no or only a small amount of this receptor on their 
surface. ORSERDU is used as monotherapy (used on its own) in patients whose cancer has not 
responded to or progressed further following at least one line of hormonal treatment including a 
CDK 4/6 inhibitor and who have certain changes (mutations) in a gene called ESR1. Your doctor will take a sample of your blood, which will be tested for these ESR1 mutations. A 
positive result is required for initiation of treatment with ORSERDU. </p>
<p>How ORSERDU works </p>
<p>Oestrogen receptors are a group of proteins found inside the cells. They are activated when the 
hormone oestrogen binds to them. By binding to these receptors, oestrogen can in some cases 
stimulate cancer cells to grow and multiply. ORSERDU contains the active substance elacestrant that 
binds to the oestrogen receptors in the cancer cells and stops them from working. By blocking and 
destroying oestrogen receptors, ORSERDU can reduce the growth and spread of breast cancer and 
help to kill cancer cells. </p>
<p>If you have any questions about how ORSERDU works or why this medicine has been prescribed for 
you, ask your doctor, pharmacist, or nurse. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take orserdu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take orserdu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use ORSERDU if:</p>
<ul>
<li>you are allergic to elacestrant or any of the other ingredients of this medicine (listed in 
section 6). </li>
</ul>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking ORSERDU </p>
<ul>
<li>if you have any liver disease (examples of liver disease include cirrhosis (scarring of the liver), 
liver impairment or cholestatic jaundice (yellowing of the skin and eyes due to a reduced flow 
of bile from the liver)). Your doctor will monitor you regularly and closely for adverse 
reactions. </li>
</ul>
<p>By having advanced breast cancer you may have an increased risk of developing blood clots in your 
veins (a type of blood vessel). It is unknown if ORSERDU also increases this risk. </p>
<p>Children and adolescents 
ORSERDU should not be given to children and adolescents under 18 years of age. </p>
<p>Other medicines and ORSERDU 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. This is because ORSERDU can affect the way some other medicines work. Also, some 
other medicines can affect the way ORSERDU works. </p>
<p>Tell your doctor if you take any of the following medicines:</p>
<ul>
<li>antibiotics to treat bacterial infections (such as ciprofloxacin, clarithromycin, erythromycin, 
rifampicin, telithromycin) </li>
<li>medicine for low blood sodium (such as conivaptan) </li>
<li>medicines to treat depression (such as nefazodone or fluvoxamine) </li>
<li>medicine to treat anxiety and alcohol withdrawal (such as tofisopam). </li>
<li>medicines for the treatment of other cancers (such as crizotinib, dabrafenib, imatinib, lorlatinib, 
or sotorasib) </li>
<li>medicines for high blood pressure or chest pain (such as bosentan, diltiazem or verapamil) </li>
<li>medicines for fungal infections (such as fluconazole, isavuconazole, itraconazole, ketoconazole, 
posaconazole, or voriconazole) </li>
<li>medicines for HIV infection (such as efavirenz, etravirine, indinavir, lopinavir, ritonavir, 
nelfinavir, saquinavir, or telaprevir) </li>
<li>medicines to treat irregular heartbeats (such as digoxin, dronedarone, or quinidine) </li>
<li>medicines used in organ transplantation to prevent rejection (such as cyclosporine) </li>
<li>medicines to prevent cardiovascular events and to treat high levels of cholesterol (such as 
rosuvastatin) </li>
<li>medicines used to prevent seizures (such as carbamazepine, cenobamate, phenobarbital, 
phenytoin, or primidone) </li>
<li>medicines to treat vomiting (such as aprepitant) </li>
<li>herbal medicines used to treat depression containing St. John s wort </li>
</ul>
<p>ORSERDU with food and drink 
Do not drink grapefruit juice or eat grapefruit while on treatment with ORSERDU as it may change 
the amount of ORSERDU in your body and increase the side effects of ORSERDU (see Section 3 
 How to take ORSERDU . </p>
<p>Pregnancy, breast-feeding and fertility 
This medicine should only be used in postmenopausal women and in men. </p>
<p>Pregnancy 
ORSERDU may harm an unborn baby. You must not take ORSERDU if you are pregnant, think you 
may be pregnant or are planning to have a baby. If you think you may be pregnant or planning to have 
a baby, ask your doctor, or pharmacist for advice before using this medicine. </p>
<p>If you are a woman who could become pregnant, you should use effective contraception while you are 
being treated with ORSERDU and for one week after stopping treatment with ORSERDU. Ask your 
doctor for suitable methods. If you are a woman who could become pregnant, your doctor will rule out 
an existing pregnancy before starting you on treatment with ORSERDU. This may include having a 
pregnancy test. </p>
<p>Breast-feeding 
You must not breast-feed while on treatment with ORSERDU and for one week after the last dose of 
ORSERDU. During treatment, your doctor will discuss the potential risks of taking ORSERDU during 
pregnancy or breast-feeding. </p>
<p>Fertility 
ORSERDU may impair fertility in women and men. </p>
<p>Driving and using machines 
ORSERDU has no or negligible influence on the ability to drive and use machines. However, since 
fatigue, weakness, and difficulty sleeping have been reported in some patients taking elacestrant, 
caution should be observed by patients who experience those adverse reactions when driving or 
operating machinery. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take orserdu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take orserdu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>ORSERDU should be taken with food, just avoid grapefruit and grapefruit juice during treatment with 
ORSERDU (see section 2  ORSERDU with food and drink ). Taking ORSERDU with food may 
reduce nausea and vomiting. </p>
<p>Take your dose of this medicine at approximately the same time each day. This will help you to 
remember to take your medicine. </p>
<p>ORSERDU tablets should be swallowed whole. They should not be chewed, crushed or split prior to 
swallowing. Do not take a tablet that is broken, cracked or otherwise damaged. </p>
<p>The recommended dose of ORSERDU is 345 mg (one 345 mg film-coated tablet) once daily. Your 
doctor will tell you exactly how many tablets to take. In certain situations (i.e. in case of liver 
problems, side effects, or if you are also using certain other medicines your doctor may instruct you to 
take a lower dose of ORSERDU, e.g. 258 mg (3 tablets of 86 mg) once daily, 172 mg (2 tablets of 
86 mg) once daily, or 86 mg (1 tablet of 86 mg) once daily. </p>
<p>If you take more ORSERDU than you should 
Tell your doctor or pharmacist if you think you have accidentally taken more ORSERDU than you 
should. He or she will decide what to do. </p>
<p>If you forget to take ORSERDU 
If you forget to take a dose of ORSERDU, take it as soon as you remember. You may still take a 
forgotten dose up to 6 hours after the time you should have taken it. If more than 6 hours have passed 
or if you vomit after taking the dose, skip the dose for that day and take the next dose at your usual 
time the next day. Do not take a double dose to make up for the one that you missed. </p>
<p>If you stop taking ORSERDU 
Do not stop using this medicine without talking to your doctor or pharmacist. If treatment with 
ORSERDU is stopped, your condition may worsen. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. 
Tell your doctor or nurse if you notice any of the following side effects: </p>
<p>Very common (may affect more than 1 in 10 people) 
* Decreased appetite 
* Feeling sick (nausea) 
* Increased triglycerides and cholesterol levels in your blood 
* Vomiting 
* Tiredness (fatigue) 
* Indigestion (dyspepsia) 
* Diarrhoea 
* Decreased calcium levels in your blood 
* Back pain 
* Increased creatinine levels in your blood 
* Joint pain (arthralgia) 
* Decreased sodium levels in your blood 
* Constipation 
* Headache 
* Hot flushes 
* Abdominal pain 
* Low levels of red blood cells, as measured in blood tests (anaemia) 
* Decreased potassium levels in your blood 
* Elevated liver function, as measured in blood tests (alanine aminotransferase increased, 
aspartate aminotransferase increased) </p>
<p>Common (may affect up to 1 in every 10 people) 
* Pain in hands or legs (pain in extremity) 
* Weakness (asthenia) 
* Infection of the parts of the body that collect and pass out urine (urinary tract infection) 
* Cough 
* Shortness of breath (dyspnoea) 
* Difficulty falling and staying asleep (insomnia) 
* Elevated liver function, as measured in blood tests (Blood alkaline phosphatase increased) 
* Rash 
* Low levels of lymphocytes (a type of white blood cell), as measured in blood tests (Lymphocyte 
count decreased) 
* Bone pain 
* Dizziness 
* Chest pain relating to the muscles and bones in the chest (Musculoskeletal chest pain) 
* Inflammation of the mouth and lips (stomatitis) 
* Fainting (syncope) </p>
<p>Uncommon (may affect up to 1 in every 100 people) 
* Increased risk of blood clots (thromboembolism) 
* Liver failure (acute hepatic failure) </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store orserdu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store orserdu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister pack after EXP. 
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not use this medicine if you notice any damage to the packaging or if there are any signs of 
tampering. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What ORSERDU contains 
- The active substance is elacestrant. 
* 
Each 86 mg ORSERDU film-coated tablet contains 86.3 mg of elacestrant. 
* 
Each 345 mg ORSERDU film-coated tablet contains 345 mg of elacestrant </p>
<ul>
<li>The other ingredients are: </li>
</ul>
<p>Tablet core 
Microcrystalline cellulose [E460] 
Silicified microcrystalline cellulose 
Crospovidone [E1202] 
Magnesium stearate [E470b] 
Colloidal silicon dioxide [E551] </p>
<p>Film-coating 
Opadry II 85F105080 Blue containing polyvinyl alcohol [E1203], titanium dioxide [E171], 
macrogol [E1521], talc [E553b] and brilliant blue FCF aluminium lake [E133] </p>
<p>What ORSERDU looks like and contents of the pack </p>
<p>ORSERDU is supplied as film-coated tablets in aluminium blisters. </p>
<p>ORSERDU 86 mg film-coated tablets 
Blue to light blue, biconvex round shaped film-coated tablet with  ME  debossed on one side and 
plain face on the opposite side. Approximate diameter: 8.8 mm. </p>
<p>ORSERDU 345 mg film-coated tablets 
Blue to light blue, biconvex, oval shaped film-coated tablet with  MH  debossed on one side and plain 
face on the opposite side. Approximate size: 19.2 mm (length), 10.8 mm (width). </p>
<p>Each pack contains 28 film-coated tablets (4 blisters with 7 tablets each). </p>
<p>Marketing Authorisation Holder 
Stemline Therapeutics B.V.<br />
Basisweg 1043 AP Amsterdam<br />
The Netherlands </p>
<p>Manufacturer 
Stemline Therapeutics B.V. 
Basisweg 1043 AP Amsterdam<br />
The Netherlands </p>
<p>or </p>
<p>Berlin Chemie AG 
Glienicker Weg 12489 Berlin 
Germany </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien;  ; 
 esk  republika; Danmark; Eesti; 
 ; Hrvatska; Ireland;  sland; 
 ; Latvija; Lietuva; 
Luxembourg/Luxemburg; 
Magyarorsz g; Malta; Nederland; 
Norge; Polska; Portugal; Rom nia; 
Slovenija; Slovensk  republika; 
Suomi/Finland; Sverige 
Stemline Therapeutics B.V. 
Tel: +44 (0)800 047 8EUmedinfo@menarinistemline.com </p>
<p>Italia 
Menarini Stemline Italia S.r.l. 
Tel: +39 800776EUmedinfo@menarinistemline.com </p>
<p>Deutschland 
Menarini Stemline Deutschland GmbH 
Tel: +49 (0)800 0008EUmedinfo@menarinistemline.com </p>
<p>sterreich 
Stemline Therapeutics B.V. 
Tel: +43 (0)800 297 EUmedinfo@menarinistemline.com 
Espa a 
Menarini Stemline Espa a, S.L.U. 
Tel: +34919490EUmedinfo@menarinistemline.com </p>
<p>United Kingdom (Northern Ireland) 
Stemline Therapeutics B.V. 
Tel: +44 (0)800 047 8EUmedinfo@menarinistemline.com </p>
<p>France 
Stemline Therapeutics B.V. 
T l: +33 (0)800 991EUmedinfo@menarinistemline.com </p>
<p>This leaflet was last revised in  </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-8fdef97116c9e46e3458e3dc3216f0d9
InstanceOf: CompositionUvEpi
Title: "Composition for orserdu Package Leaflet"
Description:  "Composition for orserdu Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp8fdef97116c9e46e3458e3dc3216f0d9)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - orserdu"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage ORSERDU 
3. Sådan skal du tage ORSERDU 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What orserdu is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What orserdu is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Virkning </p>
<p>ORSERDU indeholder det aktive stof elacestrant, som tilhører en gruppe lægemidler, der kaldes 
selektive østrogenreceptor-nedbrydere. </p>
<p>Anvendelse </p>
<p>Dette lægemiddel anvendes til behandling af postmenopausale kvinder og voksne mænd, der har en 
bestemt type brystkræft, der er fremskreden eller har spredt sig til andre dele af kroppen (metastatisk). 
Det kan bruges til behandling af brystkræft, der er østrogenreceptor (ER)-positiv, hvilket betyder, at 
kræftcellerne har receptorer for hormonet østrogen på deres overflade, og der er human epidermal 
vækstfaktorreceptor 2 (HER2)-negativ, hvilket betyder, at kræftcellerne ikke har eller kun har en lille 
mængde af denne receptor på deres overflade. ORSERDU anvendes som monoterapi (eneste 
lægemiddel) til patienter, hvis kræft ikke har reageret på eller har udviklet sig yderligere efter mindst 
én linje hormonbehandling, herunder en CDK 4/6-hæmmer, og som har bestemte ændringer 
(mutationer) i et gen kaldet ESR1. Din læge vil tage en blodprøve fra dig, som vil blive testet for disse ESR1-mutationer. Et positivt 
resultat er nødvendigt for at påbegynde behandling med ORSERDU. </p>
<p>Sådan virker ORSERDU’ </p>
<p>Østrogenreceptorer er en gruppe proteiner, der findes inde i cellerne. De aktiveres, når hormonet 
østrogen binder sig til dem. Østrogen kan ved at binde sig til disse receptorer i nogle tilfælde stimulere 
kræftcellerne til at vokse og formere sig. ORSERDU indeholder det aktive stof elacestrant, der binder 
til østrogenreceptorerne i kræftcellerne og forhindrer dem i at virke. Ved at blokere og ødelægge 
østrogenreceptorerne kan ORSERDU bremse væksten og spredningen af brystkræft og hjælpe med at 
dræbe kræftcellerne. </p>
<p>Hvis du har spørgsmål om, hvordan ORSERDU virker, eller hvorfor du har fået det ordineret, skal du 
spørge lægen, apotekspersonalet eller sygeplejersken. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take orserdu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take orserdu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke ORSERDU, hvis:</p>
<ul>
<li>du er allergisk over for elacestrant eller et af de øvrige indholdsstoffer i ORSERDU (angivet i 
punkt 6). </li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager ORSERDU, </p>
<ul>
<li>hvis du har en leversygdom (eksempler på leversygdom omfatter skrumpelever (cirrose - ardannelse i leveren), nedsat leverfunktion eller kolestatisk gulsot (gulfarvning af hud og øjne 
på grund af nedsat galdestrøm fra leveren) ). Din læge vil overvåge dig regelmæssigt og nøje for 
bivirkninger. </li>
</ul>
<p>Hvis du har fremskreden brystkræft kan du have en øget risiko for at udvikle blodpropper i venerne 
(en type blodkar). Det er ukendt, om ORSERDU også øger denne risiko. </p>
<p>Børn og unge 
ORSERDU bør ikke gives til børn og unge under 18 år. </p>
<p>Brug af andre lægemidler sammen med ORSERDU 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har taget 
andre lægemidler eller planlægger at tage andre lægemidler. Dette skyldes, at ORSERDU kan påvirke 
den måde, visse andre lægemidler virker på. Nogle andre lægemidler kan også påvirke den måde, 
ORSERDU virker på. </p>
<p>Fortæl det til lægen, hvis du tager et eller flere af følgende lægemidler:</p>
<ul>
<li>antibiotika til behandling af bakterielle infektioner (såsom ciprofloxacin, clarithromycin, 
erythromycin, rifampicin, telithromycin) </li>
<li>lægemiddel til behandling af et lavt indhold af natrium i blodet (såsom conivaptan) </li>
<li>lægemidler til behandling af depression (såsom nefazodon eller fluvoxamin) </li>
<li>lægemiddel til behandling af angst og alkoholabstinenser (såsom tofisopam) </li>
<li>lægemidler til behandling af andre former for kræft (såsom crizotinib, dabrafenib, imatinib, 
lorlatinib eller sotorasib) </li>
<li>lægemidler mod forhøjet blodtryk eller brystsmerter (såsom bosentan, diltiazem eller verapamil) </li>
<li>lægemidler mod svampeinfektioner (såsom fluconazol, isavuconazol, itraconazol, ketoconazol, 
posaconazol eller voriconazol) </li>
<li>lægemidler mod hiv-infektion (såsom efavirenz, etravirin, indinavir, lopinavir, ritonavir, 
nelfinavir, saquinavir eller telaprevir) </li>
<li>lægemidler til behandling af uregelmæssig hjerterytme (såsom digoxin, dronedaron eller 
kinidin) </li>
<li>lægemidler, der anvendes ved organtransplantation til at forhindre afstødning (såsom 
ciclosporin) </li>
<li>lægemidler til forebyggelse af kardiovaskulære hændelser og til behandling af høje niveauer af 
kolesterol (såsom rosuvastatin) </li>
<li>lægemidler, der anvendes til at forhindre krampeanfald (såsom carbamazepin, cenobamat, 
phenobarbital, phenytoin eller primidon) </li>
<li>lægemidler til behandling af opkastning (såsom aprepitant) </li>
<li>naturlægemidler, der anvendes til behandling af depression, indeholdende prikbladet perikon. </li>
</ul>
<p>Brug af ORSERDU sammen med mad og drikke 
Du må ikke drikke grapefrugtjuice eller spise grapefrugt, mens du er i behandling med ORSERDU, da 
det kan ændre mængden af ORSERDU i din krop og øge bivirkningerne ved ORSERDU (se punkt 3 
"Sådan skal du tage ORSERDU"). </p>
<p>Graviditet, amning og frugtbarhed 
Dette lægemiddel bør kun anvendes til postmenopausale kvinder og til mænd. </p>
<p>Graviditet 
ORSERDU kan skade et ufødt barn. Du må ikke tage ORSERDU, hvis du er gravid, har mistanke om, 
at du er gravid, eller planlægger at blive gravid. Hvis du har mistanke om, at du er gravid, eller 
planlægger at blive gravid, skal du spørge lægen eller apotekspersonalet til råds, før du bruger dette 
lægemiddel. </p>
<p>Hvis du er en kvinde, som kan blive gravid, skal du bruge sikker prævention, mens du behandles med 
ORSERDU og i en uge, efter at du er stoppet med behandlingen med ORSERDU. Spørg din læge om 
egnede præventionsmetoder. Hvis du er en kvinde, som kan blive gravid, vil din læge udelukke en 
eksisterende graviditet, inden du starter i behandling med ORSERDU. Dette kan omfatte at få taget en 
graviditetstest. </p>
<p>Amning 
Du må ikke amme, mens du er i behandling med ORSERDU og i en uge efter den sidste dosis af 
ORSERDU. Under behandlingen vil din læge tale med dig om de mulige risici ved at tage ORSERDU 
under graviditet eller amning. </p>
<p>Fertilitet 
ORSERDU kan nedsætte fertiliteten hos kvinder og mænd. </p>
<p>Trafik- og arbejdssikkerhed 
ORSERDU påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene 
maskiner. Der er imidlertid rapporteret træthed, svaghed og søvnbesvær hos nogle patienter, der tager 
elacestrant. Patienter, der oplever disse bivirkninger, bør udvise forsigtighed, når de fører motorkøretøj 
eller betjener maskiner. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take orserdu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take orserdu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>ORSERDU skal tages sammen med mad, dog skal grapefrugt og grapefrugtjuice undgås under 
behandlingen med ORSERDU (se punkt 2 "Brug af ORSERDU sammen med mad og drikke"). Hvis 
du tager ORSERDU sammen med mad, kan det reducere kvalme og opkastning. </p>
<p>Tag din dosis af dette lægemiddel på omtrent samme tidspunkt hver dag. Det vil hjælpe dig med huske 
at tage dit lægemiddel. </p>
<p>ORSERDU-tabletterne skal synkes hele. De må ikke tygges, knuses eller deles før de synkes. Tag ikke 
en tablet, der er knækket, knust eller på anden måde beskadiget. </p>
<p>Den anbefalede dosis af ORSERDU er 345 mg (én 345 mg filmovertrukket tablet) én gang dagligt. 
Din læge vil fortælle dig præcis, hvor mange tabletter, du skal tage. I visse situationer (dvs. i tilfælde 
af leverproblemer, bivirkninger, eller hvis du også bruger visse andre lægemidler, kan din læge bede 
dig om at tage en lavere dosis ORSERDU, f.eks. 258 mg (3 tabletter med 86 mg) én gang dagligt, 
172 mg (2 tabletter med 86 mg) én gang dagligt eller 86 mg (1 tablet med 86 mg) én gang dagligt. </p>
<p>Hvis du har taget for meget ORSERDU 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tror, at du ved et uheld har taget for meget 
ORSERDU. Han eller hun vil beslutte, hvad der skal gøres. </p>
<p>Hvis du har glemt at tage ORSERDU 
Hvis du har glemt at tage en dosis ORSERDU, skal du tage den, så snart du kommer i tanke om det. 
Du kan stadig tage en glemt dosis op til 6 timer efter det tidspunkt, du skulle have taget den på. Hvis 
der er gået mere end 6 timer, eller hvis du kaster op efter at have taget dosen, skal du springe dosis 
over for den dag, og tage den næste dosis til sædvanlig tid den næste dag. Du må ikke tage en 
dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Hvis du holder op med at tage ORSERDU 
Du må ikke holde op med at tage dette lægemiddel uden først at kontakte din læge eller 
apotekspersonalet. Hvis behandlingen med ORSERDU stoppes, kan din tilstand forværres. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. 
Fortæl det til lægen eller sygeplejersken, hvis du bemærker en eller flere af følgende bivirkninger: </p>
<p>Meget almindelige (kan forekomme hos flere end 1 ud af 10 personer) </p>
<ul>
<li>
<p>Nedsat appetit </p>
</li>
<li>
<p>Kvalme </p>
</li>
<li>
<p>Forhøjede triglycerider og kolesterolniveauer i blodet </p>
</li>
<li>
<p>Opkastning </p>
</li>
<li>
<p>Træthed </p>
</li>
<li>
<p>Fordøjelsesbesvær (dyspepsi) </p>
</li>
<li>
<p>Diarré </p>
</li>
<li>
<p>Nedsatte calciumniveauer i blodet </p>
</li>
<li>
<p>Rygsmerter </p>
</li>
<li>
<p>Forhøjede kreatininniveauer i blodet </p>
</li>
<li>
<p>Ledsmerter (artralgi) </p>
</li>
<li>
<p>Nedsatte natriumniveauer i blodet </p>
</li>
<li>
<p>Forstoppelse </p>
</li>
<li>
<p>Hovedpine </p>
</li>
<li>
<p>Hedeture </p>
</li>
<li>
<p>Mavesmerter </p>
</li>
<li>
<p>Lavt antal røde blodlegemer målt i blodprøver (anæmi) </p>
</li>
<li>
<p>Nedsatte kaliumniveauer i blodet </p>
</li>
<li>
<p>Forhøjet leverfunktion målt i blodprøver (forhøjet alaninaminotransferase, forhøjet 
aspartataminotransferase) </p>
</li>
</ul>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer) </p>
<ul>
<li>
<p>Smerter i hænder eller ben (smerter i ekstremiteter) </p>
</li>
<li>
<p>Svaghed (asteni) </p>
</li>
<li>
<p>Infektion i de dele af kroppen, der opsamler og udskiller urin (urinvejsinfektion) </p>
</li>
<li>
<p>Hoste </p>
</li>
<li>
<p>Stakåndethed (dyspnø) </p>
</li>
<li>
<p>Problemer med at falde i søvn og blive ved med at sove (insomni) </p>
</li>
<li>
<p>Forhøjet leverfunktion målt i blodprøver (forhøjet basisk fosfatase i blodet) </p>
</li>
<li>
<p>Udslæt </p>
</li>
<li>
<p>Lave niveauer af lymfocytter (en type hvide blodlegemer) målt i blodprøver (nedsat 
lymfocyttal) </p>
</li>
<li>
<p>Knoglesmerter </p>
</li>
<li>
<p>Svimmelhed </p>
</li>
<li>
<p>Brystsmerter relateret til muskler og knogler i brystet (muskuloskeletale brystsmerter) </p>
</li>
<li>
<p>Betændelse i mund og læber (stomatitis) </p>
</li>
<li>
<p>Besvimelse (synkope) </p>
</li>
</ul>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer) </p>
<ul>
<li>
<p>Øget risiko for blodpropper (tromboembolisme) </p>
</li>
<li>
<p>Leversvigt (akut leversvigt) </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store orserdu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store orserdu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og blisterpakningen efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Brug ikke lægemidlet, hvis du bemærker, at pakningen er beskadiget, eller hvis der er tegn på, at 
nogen har forsøgt at åbne den. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du 
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>ORSERDU indeholder:</p>
<ul>
<li>
<p>Aktivt stof: elacestrant. </p>
</li>
<li>
<p>Hver 86 mg ORSERDU filmovertrukket tablet indeholder 86,3 mg elacestrant. </p>
</li>
<li>
<p>Hver 345 mg ORSERDU filmovertrukket tablet indeholder 345 mg elacestrant </p>
</li>
<li>
<p>Øvrige indholdsstoffer: </p>
</li>
</ul>
<p>Tabletkerne 
Mikrokrystallinsk cellulose [E460] 
Silicificeret mikrokrystallinsk cellulose 
Crospovidon [E1202] 
Magnesiumstearat [E470b] 
Silica, kolloid [E551] </p>
<p>Filmovertræk 
Opadry II 85F105080 Blue indeholdende polyvinylalkohol [E1203], titandioxid [E171], 
macrogol [E1521], talcum [E553b] og brilliant blue FCF aluminum lake [E133] </p>
<p>Udseende og pakningsstørrelser </p>
<p>ORSERDU leveres som filmovertrukne tabletter i aluminiumsblistre. </p>
<p>ORSERDU 86 mg filmovertrukne tabletter 
Blå til lyseblå, bikonveks, rund filmovertrukket tablet med "ME" præget på den ene side og glat 
overflade på den anden side. Omtrentlig diameter: 8,8 mm. </p>
<p>ORSERDU 345 mg filmovertrukne tabletter 
Blå til lyseblå, bikonveks, oval filmovertrukket tablet med "MH" præget på den ene side og glat 
overflade på den anden side. Omtrentlig størrelse: 19,2 mm (længde), 10,8 mm (bredde) </p>
<p>Hver pakning indeholder 28 filmovertrukne tabletter (4 blistre med 7 tabletter i hver). </p>
<p>Indehaver af markedsføringstilladelsen 
Stemline Therapeutics B.V.<br />
Basisweg 10<br />
1043 AP Amsterdam<br />
Holland </p>
<p>Fremstiller 
Stemline Therapeutics B.V. 
Basisweg 10<br />
1043 AP Amsterdam<br />
Holland </p>
<p>eller </p>
<p>Berlin Chemie AG 
Glienicker Weg 12489 Berlin 
Tyskland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien; България; 
Česká republika; Danmark; Eesti; 
Ελλάδα; Hrvatska; Ireland; Ísland; 
Κύπρος; Latvija; Lietuva; 
Luxembourg/Luxemburg; 
Magyarország; Malta; Nederland; 
Norge; Polska; Portugal; România; 
Slovenija; Slovenská republika; 
Suomi/Finland; Sverige 
Stemline Therapeutics B.V. 
Tel: +44 (0)800 047 8EUmedinfo@menarinistemline.com </p>
<p>Italia 
Menarini Stemline Italia Srl 
Tel: +39 800776EUmedinfo@menarinistemline.com </p>
<p>Deutschland 
Menarini Stemline Deutschland GmbH 
Tel: +49 (0)800 0008EUmedinfo@menarinistemline.com </p>
<p>Österreich 
Stemline Therapeutics B.V. 
Tel: +43 (0)800 297 EUmedinfo@menarinistemline.com 
España 
Menarini Stemline España, S.L.U. 
Tel: +34919490EUmedinfo@menarinistemline.com </p>
<p>United Kingdom (Northern Ireland) 
Stemline Therapeutics B.V. 
Tel: +44 (0)800 047 8EUmedinfo@menarinistemline.com </p>
<p>France 
Stemline Therapeutics B.V. 
Tél: +33 (0)800 991EUmedinfo@menarinistemline.com </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-8fdef97116c9e46e3458e3dc3216f0d9
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for orserdu Package Leaflet for language en"
Description: "ePI document Bundle for orserdu Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-8fdef97116c9e46e3458e3dc3216f0d9"
* entry[0].resource = composition-en-8fdef97116c9e46e3458e3dc3216f0d9

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8fdef97116c9e46e3458e3dc3216f0d9"
* entry[=].resource = mp8fdef97116c9e46e3458e3dc3216f0d9
                            
                    
Instance: bundlepackageleaflet-da-8fdef97116c9e46e3458e3dc3216f0d9
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for orserdu Package Leaflet for language da"
Description: "ePI document Bundle for orserdu Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-8fdef97116c9e46e3458e3dc3216f0d9"
* entry[0].resource = composition-da-8fdef97116c9e46e3458e3dc3216f0d9

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8fdef97116c9e46e3458e3dc3216f0d9"
* entry[=].resource = mp8fdef97116c9e46e3458e3dc3216f0d9
                            
                    



Instance: mp8fdef97116c9e46e3458e3dc3216f0d9
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product ORSERDU 86 mg film-coated tablets"
Description: "ORSERDU 86 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/23/1756/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "ORSERDU 86 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 8fdef97116c9e46e3458e3dc3216f0d9ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "orserdu"

* status = #current
* mode = #working

* title = "List of all ePIs associated with orserdu"

* subject = Reference(mp8fdef97116c9e46e3458e3dc3216f0d9)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#orserdu "orserdu"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-8fdef97116c9e46e3458e3dc3216f0d9) // orserdu en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-8fdef97116c9e46e3458e3dc3216f0d9) // orserdu da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-8fdef97116c9e46e3458e3dc3216f0d9
InstanceOf: List

* insert 8fdef97116c9e46e3458e3dc3216f0d9ListRuleset
    